On February 12, 2026, Realbotix Corp., a TSXV‑listed company focused on the design and manufacture of AI‑powered humanoid robots, entered into a definitive agreement with Onconetix, Inc., a NASDAQ‑listed issuer, pursuant to which Onconetix will acquire 100% of the membership interests of Realbotix, LLC, an indirect, wholly-owned, non-core subsidiary of Realbotix, in an all‑stock transaction. Under the terms of the transaction, Realbotix is expected to receive between 75% and 90% of the fully-diluted equity of Onconetix following closing, with the final ownership percentage determined based on Onconetix’s net cash position at closing. Following completion of the transaction, Realbotix will retain the right to appoint a majority of the board of directors of Onconetix. The transaction is expected to close prior to the end of the third quarter of 2026, subject to the satisfaction or waiver of customary closing conditions, including regulatory and shareholder approvals.
Cassels acted for Realbotix.